Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day
(firmenpresse) - LEXINGTON, MA -- (Marketwired) -- 02/06/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017.
2017 Rare Disease, Biopharma One-on-One Day
Tuesday, February 7, 2017
Intercontinental Barclay, 111 E 48th St, New York, NY
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra''s lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra''s product candidates have not been approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.02.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 1484745
Anzahl Zeichen: 3009
contact information:
Contact person:
Town:
LEXINGTON, MA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day
"
steht unter der journalistisch-redaktionellen Verantwortung von
Aldeyra Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
